Statistics

Total Visits

Views
Erlotinib as second-line therapy for patients with advanced non-small-cell lung cancer and wild-type EGFR tumors8

Select a period of time:

Number of views in the range

Views
Erlotinib as second-line therapy for patients with advanced non-small-cell lung cancer and wild-type EGFR tumors6

Views

Views
November 20230
December 20231
January 20241
February 20240
March 20242
April 20240
May 20242
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States6
 

Top cities views

Views
Boardman2
Ashburn1
Chicago1